Immuneering Corp (IMRX)
CIK 1790340 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Fewer than two cover-page share counts on file, so there is no history to chart.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Purchase Warrants | 2.8M | $5.5 | — | — |
| Pre Funded Warrants | 1.1M | $3.949 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 5, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 308,308 underlying shares, as reported Jun 30, 2021 (10-Q).
Reported exercise price: $3.01 (aggregate figure as tagged; individual tranches vary).
Balance-sheet fair value of warrants: $0 as of Dec 31, 2021.
Rough fully diluted estimate: 26.2M = 25.9M O/S + 308,308 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
No convertible-note facts tagged in the 10-Q filed Aug 5, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 25.9M | Sep 3, 2021 |
| + Purchase Warrants (if exercised) | 2.8M | Jun 30, 2026 |
| + Pre Funded Warrants (if exercised) | 1.1M | Oct 6, 2025 |
| Fully diluted estimate | 29.9M | +15.1% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $349.1Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 4 executed · 1 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full IMRX workspace